Table 1 Patient characteristics of each group
From: Serum metabolomic profile as a means to distinguish stage of colorectal cancer
| Â | Â | Liver-only | Extra-hepatic | P | ||
|---|---|---|---|---|---|---|
| Â | Locoregional CRC: group 1 (N = 42) | metastases: group 2 (N = 45) | metastases: group 3 (N = 25) | Group 1 versus group 2 | Group 2 versus group 3 | Locoregional CRC versus all stage IV |
Age (years) | 72 ± 11 | 67 ± 13 | 63 ± 13 | 0.05 | 0.19 | 0.004 |
Gender | Â | Â | Â | 0.06 | 0.50 | 0.39 |
   Male | 21 (50) | 31 (69) | 15 (60) |  |  |  |
   Female | 21 (50) | 14 (31) | 10 (40) |  |  |  |
Bowel prep | 39 (100) | 45 (100) | 25 (100) | NS | NS | NS |
Stage | Â | Â | Â | Â | Â | Â |
   Stage II | 21 | 0 | 0 |  |  |  |
   Stage III | 21 | 0 | 0 |  |  |  |
   Stage IV | 0 | 45 | 25 |  |  |  |
Any chemotherapy within 3 months | 5 (21) | 16 (36) | 9 (36) | 0.02 | 0.79 | 0.02 |
Specific chemotherapeutic agents | Â | Â | Â | Â | Â | Â |
   5-FU | 5 (100) | 15 (94) | 7 (78) |  |  |  |
   Oxaliplatin | 1 (20) | 7 (44) | 4 (44) |  |  |  |
   Irinotecan | 0 (0) | 10 (63) | 2 (22) |  |  |  |
   Bevacizumab | 0 (0) | 2 (13) | 0 (0) |  |  |  |
   Other chemotherapy | 1 (20) | 1 (6) | 2 (22) |  |  |  |